Emerging therapies for relapsing multiple sclerosis.
Six agents are currently approved by regulatory agencies to treat relapsing multiple sclerosis. Although these agents are effective and generally safe, some patients have continued disease activity or adverse effects. A sizable number of new agents are under investigation currently. This article reviews emerging agents that have shown promise in phase 2 trials.
Cohen
Jeffrey A
JA
Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland Clinic, Cleveland, Ohio 44195, USA. cohenj@ccf.org
D002986:Clinical Trials as Topic; D004638:Emergency Treatment / Q000379:methods*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D004964:Estriol / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D020528:Multiple Sclerosis, Chronic Progressive / Q000188:drug therapy*
D004791:Enzyme Inhibitors; D007155:Immunologic Factors; D004964:Estriol